HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E.l.f. Hoists 2023 Full-Year Sales Guidance As Value Prices Attract New Customers

Executive Summary

E.l.f. Beauty’s sales grew 26% to $122.6m in the fiscal 2023 first quarter, leading the Oakland, CA-based firm to increase full-year projections. According to company leadership, e.l.f. is capturing market share at a rapid clip while expanding distribution, notably in pharmacy retail.

You may also be interested in...



E.l.f. Continues To Win With Value Pricing, Youth Appeal; 33% Growth In Second Quarter

The firm is targeting 22%-24% net sales growth for the fiscal full year ended 31 March 2023 after reporting its 15th consecutive quarter of growth.

Prestige Beauty Lines Ring In Holiday Season Riding Sales Growth, Reining In Price Increases

Prestige beauty sales should be strong through year-end with high-income consumer base less likely to feel squeeze of inflation, NPD Group forecasts. In 2022 first half, US consumers with more than $100,000 household incomes spent nearly $9bn on beauty products, a 14% increase.

E.l.f. Beauty Posts ESG Stats; IFF Opens Singapore Innovation Center; Beauty News In Brief

E.l.f. Beauty’s inaugural Impact Report, IFF’s $30m investment in Singapore, Shiseido Europe’s acquisition of skin microbiome product specialist Gallinée, and more beauty news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel